| 摘要 |
Disclosed is an antibody characterised by having the following properties of: (a) specifically binding to B7-H3; (b) having an antibody-dependent phagocytosis (ADCP) activity; and cell-mediated (c) having an in vivo anti-tumour activity, or a functional fragment of the antibody, wherein said antibody or functional fragment thereof comprises: CDRH1 consisting of an amino acid sequence represented by NYVMH, CDRH2 consisting of an amino acid sequence represented by YINPYNDDVKYNEKFK, and CDRH3 consisting of an amino acid sequence represented by WGYYGSPLYYFDY as complementarity determining regions of the heavy chain; and comprises CDRL1 consisting of an amino acid sequence represented by RASSRLIYMH, CDRL2 consisting of an amino acid sequence represented by ATSNLAS, and CDRL3 consisting of an amino acid sequence represented by QQWNSNPPT as complementarity determining regions of the light chain. Also disclosed is the use of such an antibody for the manufacture of a medicament for treatment of cancer. |
